ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2012
Inhibition of opioid transmission at the μ-opioid receptor prevents both food seeking and binge-like eating.
Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it, 109 citations in OpenAlex.
- Systematic Review of Binge Eating Rodent Models for Developing Novel or Repurposing Existing Pharmacotherapies.Biomolecules · 2023Pooled it
- Opioid Antagonists and the A118G Polymorphism in the μ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2016Trial
- Effects of the mu-opioid receptor antagonist GSK1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjects.Molecular psychiatry · 2013Trial
- Neural and behavioral effects of a novel mu opioid receptor antagonist in binge-eating obese people.Biological psychiatry · 2013Trial
- Effects of mu opioid receptor antagonism on cognition in obese binge-eating individuals.Psychopharmacology · 2012Trial
- The Endogenous Opioid System in Compulsive Eating.Brain sciences · 2026Review
- Contributions of the interaction between mu-opioid receptors and dopamine receptors in the regulation of risky decision making.Progress in neuro-psychopharmacology & biological psychiatry · 2026Article
- Translational Perspectives on Binge-Eating: Insights from Animal Models.Current psychiatry reports · 2026Review
- Chronic administration of methocinnamox, a mu-opioid receptor antagonist, reduces hedonic response without impacting motivation in mice.Psychopharmacology · 2025Article
- Endocrine and Metabolic Mechanisms Linking Obesity to Type 2 Diabetes: Implications for Targeted Therapy.Healthcare (Basel, Switzerland) · 2025Review
- Current perspectives on brain circuits involved in food addiction-like behaviors.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- Prefrontal representation of affective stimuli: importance of stress, sex, and context.Cerebral cortex (New York, N.Y. : 1991) · 2023Article
- The Role of Beta-Endorphin in Food Deprivation-Mediated Increases in Food Intake and Binge-Eating.Brain sciences · 2023Article
- Linking drug and food addiction: an overview of the shared neural circuits and behavioral phenotype.Frontiers in behavioral neuroscience · 2023Review
- Pituitary adenylate cyclase-activating polypeptide type 1 receptor within the nucleus accumbens core mediates excessive alcohol drinking in alcohol-preferring rats.Neuropharmacology · 2022Article
- Chronic Intermittent Sucrose Consumption Facilitates the Ability to Discriminate Opioid Receptor Blockade with Naltrexone in Rats.Nutrients · 2022Article
- Loss of Corticostriatal Mu-Opioid Receptors in α-Synuclein Transgenic Mouse Brains.Life (Basel, Switzerland) · 2022Article
- Anhedonia in Eating Disorders.Current topics in behavioral neurosciences · 2022Article
- Predictive and motivational factors influencing anticipatory contrast: A comparison of contextual and gustatory predictors in food restricted and free-fed rats.Physiology & behavior · 2021Article
- Lessons learned from using fMRI in the early clinical development of a mu-opioid receptor antagonist for disorders of compulsive consumption.Psychopharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Endogenous opioids, and in particular μ-opioid receptors, have been linked to hedonic and rewarding mechanisms engaged during palatable food intake. The aim of this study was to investigate the effects of GSK1521498, a novel μ-opioid receptor antagonist, on food-seeking behavior and on binge-like eating of a highly preferred chocolate diet. Food seeking was measured in rats trained to respond for chocolate under a second-order schedule of reinforcement, in which prolonged periods of food-seeking behavior were maintained by contingent presentation of a reward-associated conditioned reinforcer. After reaching a stable baseline in both procedures, animals were treated with GSK1521498 (0.1, 1, and 3 mg/kg; IP) or naltrexone (NTX, 0.1, 1, and 3 mg/kg; SC). The binge eating model was characterized by four temporally contiguous phases: 1-h chow access, 2-h food deprivation, 10-min chow access, and 10-min access to either chocolate-flavoured food or standard chow. During training the rats developed binge-like hyperphagia of palatable food and anticipatory chow hypophagia (anticipatory negative contrast). Both compounds reduced binge-like palatable food hyperphagia. However, GSK1521498 reduced the impact of high hedonic value on ingestion more specifically than NTX, abolishing anticipatory chow hypophagia. GSK1521498 also dose-dependently reduced food seeking both before and after food ingestion, whereas NTX reduced food seeking only after food ingestion. Thus, while both drugs affected the hedonic value of the preferred food, GSK1521498 also directly decreased incentive motivation for chocolate. Selective μ-opioid receptor antagonism by GSK1521498 may have utility as a treatment for reducing maladaptive, palatability-driven eating behavior by reducing the motivational properties of stimuli that elicit the binge eating commonly associated with obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.